nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—SLC22A1—Indinavir—acquired immunodeficiency syndrome	0.0997	0.192	CbGbCtD
Pramipexole—SLC22A1—Nelfinavir—acquired immunodeficiency syndrome	0.0968	0.186	CbGbCtD
Pramipexole—SLC22A2—Zidovudine—acquired immunodeficiency syndrome	0.0966	0.186	CbGbCtD
Pramipexole—SLC22A1—Saquinavir—acquired immunodeficiency syndrome	0.0876	0.168	CbGbCtD
Pramipexole—SLC22A2—Lamivudine—acquired immunodeficiency syndrome	0.0748	0.144	CbGbCtD
Pramipexole—SLC22A1—Lamivudine—acquired immunodeficiency syndrome	0.0649	0.125	CbGbCtD
Pramipexole—DRD1—nerve—acquired immunodeficiency syndrome	0.00355	0.0654	CbGeAlD
Pramipexole—DRD2—nerve—acquired immunodeficiency syndrome	0.0021	0.0386	CbGeAlD
Pramipexole—HTR1A—blood plasma—acquired immunodeficiency syndrome	0.00176	0.0323	CbGeAlD
Pramipexole—HTR2A—nerve—acquired immunodeficiency syndrome	0.00138	0.0255	CbGeAlD
Pramipexole—DRD5—lymphoid tissue—acquired immunodeficiency syndrome	0.00137	0.0252	CbGeAlD
Pramipexole—ADRA2A—blood plasma—acquired immunodeficiency syndrome	0.00123	0.0227	CbGeAlD
Pramipexole—DRD4—brain—acquired immunodeficiency syndrome	0.00121	0.0223	CbGeAlD
Pramipexole—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00118	0.0217	CbGeAlD
Pramipexole—SLC22A2—digestive system—acquired immunodeficiency syndrome	0.00116	0.0213	CbGeAlD
Pramipexole—DRD3—nervous system—acquired immunodeficiency syndrome	0.00112	0.0205	CbGeAlD
Pramipexole—DRD3—central nervous system—acquired immunodeficiency syndrome	0.00107	0.0198	CbGeAlD
Pramipexole—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00105	0.0193	CbGeAlD
Pramipexole—DRD5—nervous system—acquired immunodeficiency syndrome	0.00105	0.0192	CbGeAlD
Pramipexole—DRD5—central nervous system—acquired immunodeficiency syndrome	0.00101	0.0185	CbGeAlD
Pramipexole—HTR2B—skin of body—acquired immunodeficiency syndrome	0.000942	0.0173	CbGeAlD
Pramipexole—DRD2—retina—acquired immunodeficiency syndrome	0.000869	0.016	CbGeAlD
Pramipexole—DRD3—brain—acquired immunodeficiency syndrome	0.000853	0.0157	CbGeAlD
Pramipexole—DRD5—brain—acquired immunodeficiency syndrome	0.000799	0.0147	CbGeAlD
Pramipexole—DRD1—nervous system—acquired immunodeficiency syndrome	0.000799	0.0147	CbGeAlD
Pramipexole—SLC22A1—blood—acquired immunodeficiency syndrome	0.000779	0.0143	CbGeAlD
Pramipexole—DRD1—central nervous system—acquired immunodeficiency syndrome	0.000769	0.0142	CbGeAlD
Pramipexole—HTR1B—spinal cord—acquired immunodeficiency syndrome	0.000768	0.0141	CbGeAlD
Pramipexole—HTR2B—digestive system—acquired immunodeficiency syndrome	0.000754	0.0139	CbGeAlD
Pramipexole—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.000736	0.0136	CbGeAlD
Pramipexole—SLC22A1—vagina—acquired immunodeficiency syndrome	0.000722	0.0133	CbGeAlD
Pramipexole—HTR2B—blood—acquired immunodeficiency syndrome	0.000718	0.0132	CbGeAlD
Pramipexole—HTR2B—vagina—acquired immunodeficiency syndrome	0.000666	0.0122	CbGeAlD
Pramipexole—HTR1B—nervous system—acquired immunodeficiency syndrome	0.000647	0.0119	CbGeAlD
Pramipexole—SLC22A1—nervous system—acquired immunodeficiency syndrome	0.000632	0.0116	CbGeAlD
Pramipexole—HTR2B—lung—acquired immunodeficiency syndrome	0.000629	0.0116	CbGeAlD
Pramipexole—HTR1D—nervous system—acquired immunodeficiency syndrome	0.000627	0.0115	CbGeAlD
Pramipexole—HTR1B—central nervous system—acquired immunodeficiency syndrome	0.000623	0.0115	CbGeAlD
Pramipexole—HTR2C—nervous system—acquired immunodeficiency syndrome	0.00062	0.0114	CbGeAlD
Pramipexole—HTR1A—spinal cord—acquired immunodeficiency syndrome	0.00062	0.0114	CbGeAlD
Pramipexole—DRD1—brain—acquired immunodeficiency syndrome	0.00061	0.0112	CbGeAlD
Pramipexole—SLC22A1—central nervous system—acquired immunodeficiency syndrome	0.000609	0.0112	CbGeAlD
Pramipexole—HTR1D—central nervous system—acquired immunodeficiency syndrome	0.000603	0.0111	CbGeAlD
Pramipexole—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.000597	0.011	CbGeAlD
Pramipexole—HTR2B—nervous system—acquired immunodeficiency syndrome	0.000583	0.0107	CbGeAlD
Pramipexole—HTR2A—retina—acquired immunodeficiency syndrome	0.000573	0.0105	CbGeAlD
Pramipexole—ADRA2C—blood—acquired immunodeficiency syndrome	0.000565	0.0104	CbGeAlD
Pramipexole—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.000561	0.0103	CbGeAlD
Pramipexole—ADRA2C—spinal cord—acquired immunodeficiency syndrome	0.000544	0.01	CbGeAlD
Pramipexole—ADRA2C—vagina—acquired immunodeficiency syndrome	0.000524	0.00964	CbGeAlD
Pramipexole—HTR1A—nervous system—acquired immunodeficiency syndrome	0.000522	0.00961	CbGeAlD
Pramipexole—DRD2—lung—acquired immunodeficiency syndrome	0.00051	0.00938	CbGeAlD
Pramipexole—HTR1A—central nervous system—acquired immunodeficiency syndrome	0.000503	0.00925	CbGeAlD
Pramipexole—ADRA2C—lung—acquired immunodeficiency syndrome	0.000495	0.00912	CbGeAlD
Pramipexole—HTR1B—brain—acquired immunodeficiency syndrome	0.000495	0.0091	CbGeAlD
Pramipexole—SLC22A1—brain—acquired immunodeficiency syndrome	0.000483	0.00889	CbGeAlD
Pramipexole—HTR1D—brain—acquired immunodeficiency syndrome	0.000479	0.00881	CbGeAlD
Pramipexole—HTR2C—brain—acquired immunodeficiency syndrome	0.000474	0.00873	CbGeAlD
Pramipexole—DRD2—nervous system—acquired immunodeficiency syndrome	0.000472	0.00868	CbGeAlD
Pramipexole—ADRA2C—nervous system—acquired immunodeficiency syndrome	0.000459	0.00844	CbGeAlD
Pramipexole—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000454	0.00836	CbGeAlD
Pramipexole—ADRA2A—blood—acquired immunodeficiency syndrome	0.000451	0.0083	CbGeAlD
Pramipexole—HTR2B—brain—acquired immunodeficiency syndrome	0.000445	0.0082	CbGeAlD
Pramipexole—ADRA2C—central nervous system—acquired immunodeficiency syndrome	0.000442	0.00813	CbGeAlD
Pramipexole—ADRA2A—spinal cord—acquired immunodeficiency syndrome	0.000434	0.00799	CbGeAlD
Pramipexole—HTR2B—lymph node—acquired immunodeficiency syndrome	0.00043	0.00792	CbGeAlD
Pramipexole—ADRA2A—vagina—acquired immunodeficiency syndrome	0.000418	0.00769	CbGeAlD
Pramipexole—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000402	0.00741	CbGeAlD
Pramipexole—HTR1A—brain—acquired immunodeficiency syndrome	0.000399	0.00735	CbGeAlD
Pramipexole—ADRA2A—lung—acquired immunodeficiency syndrome	0.000395	0.00727	CbGeAlD
Pramipexole—HTR2A—blood—acquired immunodeficiency syndrome	0.000383	0.00706	CbGeAlD
Pramipexole—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000369	0.0068	CbGeAlD
Pramipexole—ADRA2A—nervous system—acquired immunodeficiency syndrome	0.000366	0.00674	CbGeAlD
Pramipexole—DRD2—brain—acquired immunodeficiency syndrome	0.000361	0.00664	CbGeAlD
Pramipexole—HTR2A—vagina—acquired immunodeficiency syndrome	0.000355	0.00654	CbGeAlD
Pramipexole—ADRA2A—central nervous system—acquired immunodeficiency syndrome	0.000352	0.00649	CbGeAlD
Pramipexole—ADRA2C—brain—acquired immunodeficiency syndrome	0.000351	0.00645	CbGeAlD
Pramipexole—ADRA2C—lymph node—acquired immunodeficiency syndrome	0.000339	0.00624	CbGeAlD
Pramipexole—HTR2A—lung—acquired immunodeficiency syndrome	0.000336	0.00619	CbGeAlD
Pramipexole—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000311	0.00573	CbGeAlD
Pramipexole—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.0003	0.00551	CbGeAlD
Pramipexole—ADRA2A—brain—acquired immunodeficiency syndrome	0.00028	0.00515	CbGeAlD
Pramipexole—ADRA2A—lymph node—acquired immunodeficiency syndrome	0.00027	0.00498	CbGeAlD
Pramipexole—HTR2A—brain—acquired immunodeficiency syndrome	0.000238	0.00438	CbGeAlD
Pramipexole—Anxiety—Ritonavir—acquired immunodeficiency syndrome	9.28e-05	0.000261	CcSEcCtD
Pramipexole—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	9.25e-05	0.000261	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	9.25e-05	0.000261	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	9.22e-05	0.00026	CcSEcCtD
Pramipexole—Pruritus—Abacavir—acquired immunodeficiency syndrome	9.21e-05	0.000259	CcSEcCtD
Pramipexole—Fatigue—Indinavir—acquired immunodeficiency syndrome	9.21e-05	0.000259	CcSEcCtD
Pramipexole—Anorexia—Delavirdine—acquired immunodeficiency syndrome	9.2e-05	0.000259	CcSEcCtD
Pramipexole—Discomfort—Ritonavir—acquired immunodeficiency syndrome	9.2e-05	0.000259	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	9.19e-05	0.000259	CcSEcCtD
Pramipexole—Cough—Saquinavir—acquired immunodeficiency syndrome	9.19e-05	0.000259	CcSEcCtD
Pramipexole—Constipation—Indinavir—acquired immunodeficiency syndrome	9.13e-05	0.000257	CcSEcCtD
Pramipexole—Pain—Indinavir—acquired immunodeficiency syndrome	9.13e-05	0.000257	CcSEcCtD
Pramipexole—Insomnia—Efavirenz—acquired immunodeficiency syndrome	9.13e-05	0.000257	CcSEcCtD
Pramipexole—Urticaria—Zidovudine—acquired immunodeficiency syndrome	9.12e-05	0.000257	CcSEcCtD
Pramipexole—Convulsion—Saquinavir—acquired immunodeficiency syndrome	9.12e-05	0.000257	CcSEcCtD
Pramipexole—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	9.11e-05	0.000257	CcSEcCtD
Pramipexole—Hypertension—Saquinavir—acquired immunodeficiency syndrome	9.09e-05	0.000256	CcSEcCtD
Pramipexole—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	9.08e-05	0.000256	CcSEcCtD
Pramipexole—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	9.08e-05	0.000256	CcSEcCtD
Pramipexole—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	9.07e-05	0.000255	CcSEcCtD
Pramipexole—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	9.06e-05	0.000255	CcSEcCtD
Pramipexole—Malaise—Lamivudine—acquired immunodeficiency syndrome	9.06e-05	0.000255	CcSEcCtD
Pramipexole—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	9.04e-05	0.000255	CcSEcCtD
Pramipexole—Nausea—Didanosine—acquired immunodeficiency syndrome	9.04e-05	0.000255	CcSEcCtD
Pramipexole—Vertigo—Lamivudine—acquired immunodeficiency syndrome	9.02e-05	0.000254	CcSEcCtD
Pramipexole—Hypotension—Delavirdine—acquired immunodeficiency syndrome	9.02e-05	0.000254	CcSEcCtD
Pramipexole—Syncope—Lamivudine—acquired immunodeficiency syndrome	9.01e-05	0.000254	CcSEcCtD
Pramipexole—Confusional state—Ritonavir—acquired immunodeficiency syndrome	9e-05	0.000254	CcSEcCtD
Pramipexole—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	9e-05	0.000253	CcSEcCtD
Pramipexole—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	8.99e-05	0.000253	CcSEcCtD
Pramipexole—Somnolence—Efavirenz—acquired immunodeficiency syndrome	8.97e-05	0.000253	CcSEcCtD
Pramipexole—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	8.96e-05	0.000252	CcSEcCtD
Pramipexole—Chest pain—Saquinavir—acquired immunodeficiency syndrome	8.96e-05	0.000252	CcSEcCtD
Pramipexole—Myalgia—Saquinavir—acquired immunodeficiency syndrome	8.96e-05	0.000252	CcSEcCtD
Pramipexole—Anxiety—Saquinavir—acquired immunodeficiency syndrome	8.93e-05	0.000252	CcSEcCtD
Pramipexole—Oedema—Ritonavir—acquired immunodeficiency syndrome	8.93e-05	0.000251	CcSEcCtD
Pramipexole—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.9e-05	0.000251	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.9e-05	0.000251	CcSEcCtD
Pramipexole—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	8.88e-05	0.00025	CcSEcCtD
Pramipexole—Discomfort—Saquinavir—acquired immunodeficiency syndrome	8.86e-05	0.000249	CcSEcCtD
Pramipexole—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	8.83e-05	0.000249	CcSEcCtD
Pramipexole—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	8.8e-05	0.000248	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	8.8e-05	0.000248	CcSEcCtD
Pramipexole—Shock—Ritonavir—acquired immunodeficiency syndrome	8.78e-05	0.000247	CcSEcCtD
Pramipexole—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.77e-05	0.000247	CcSEcCtD
Pramipexole—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	8.77e-05	0.000247	CcSEcCtD
Pramipexole—Cough—Lamivudine—acquired immunodeficiency syndrome	8.76e-05	0.000247	CcSEcCtD
Pramipexole—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.76e-05	0.000247	CcSEcCtD
Pramipexole—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.75e-05	0.000247	CcSEcCtD
Pramipexole—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	8.74e-05	0.000246	CcSEcCtD
Pramipexole—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.74e-05	0.000246	CcSEcCtD
Pramipexole—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	8.73e-05	0.000246	CcSEcCtD
Pramipexole—Insomnia—Delavirdine—acquired immunodeficiency syndrome	8.73e-05	0.000246	CcSEcCtD
Pramipexole—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	8.71e-05	0.000245	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.71e-05	0.000245	CcSEcCtD
Pramipexole—Convulsion—Lamivudine—acquired immunodeficiency syndrome	8.7e-05	0.000245	CcSEcCtD
Pramipexole—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.7e-05	0.000245	CcSEcCtD
Pramipexole—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.7e-05	0.000245	CcSEcCtD
Pramipexole—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.67e-05	0.000244	CcSEcCtD
Pramipexole—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	8.67e-05	0.000244	CcSEcCtD
Pramipexole—Confusional state—Saquinavir—acquired immunodeficiency syndrome	8.66e-05	0.000244	CcSEcCtD
Pramipexole—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	8.63e-05	0.000243	CcSEcCtD
Pramipexole—Pain—Efavirenz—acquired immunodeficiency syndrome	8.63e-05	0.000243	CcSEcCtD
Pramipexole—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.63e-05	0.000243	CcSEcCtD
Pramipexole—Rash—Nevirapine—acquired immunodeficiency syndrome	8.63e-05	0.000243	CcSEcCtD
Pramipexole—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8.62e-05	0.000243	CcSEcCtD
Pramipexole—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	8.61e-05	0.000242	CcSEcCtD
Pramipexole—Dizziness—Abacavir—acquired immunodeficiency syndrome	8.61e-05	0.000242	CcSEcCtD
Pramipexole—Oedema—Saquinavir—acquired immunodeficiency syndrome	8.59e-05	0.000242	CcSEcCtD
Pramipexole—Somnolence—Delavirdine—acquired immunodeficiency syndrome	8.58e-05	0.000242	CcSEcCtD
Pramipexole—Headache—Nevirapine—acquired immunodeficiency syndrome	8.57e-05	0.000241	CcSEcCtD
Pramipexole—Myalgia—Lamivudine—acquired immunodeficiency syndrome	8.55e-05	0.000241	CcSEcCtD
Pramipexole—Chest pain—Lamivudine—acquired immunodeficiency syndrome	8.55e-05	0.000241	CcSEcCtD
Pramipexole—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	8.55e-05	0.000241	CcSEcCtD
Pramipexole—Infection—Saquinavir—acquired immunodeficiency syndrome	8.54e-05	0.00024	CcSEcCtD
Pramipexole—Anxiety—Lamivudine—acquired immunodeficiency syndrome	8.52e-05	0.00024	CcSEcCtD
Pramipexole—Anorexia—Ritonavir—acquired immunodeficiency syndrome	8.51e-05	0.00024	CcSEcCtD
Pramipexole—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	8.5e-05	0.000239	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	8.49e-05	0.000239	CcSEcCtD
Pramipexole—Urticaria—Indinavir—acquired immunodeficiency syndrome	8.48e-05	0.000239	CcSEcCtD
Pramipexole—Shock—Saquinavir—acquired immunodeficiency syndrome	8.45e-05	0.000238	CcSEcCtD
Pramipexole—Discomfort—Lamivudine—acquired immunodeficiency syndrome	8.45e-05	0.000238	CcSEcCtD
Pramipexole—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	8.44e-05	0.000238	CcSEcCtD
Pramipexole—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	8.44e-05	0.000238	CcSEcCtD
Pramipexole—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	8.43e-05	0.000237	CcSEcCtD
Pramipexole—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	8.43e-05	0.000237	CcSEcCtD
Pramipexole—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	8.41e-05	0.000237	CcSEcCtD
Pramipexole—Vomiting—Stavudine—acquired immunodeficiency syndrome	8.4e-05	0.000237	CcSEcCtD
Pramipexole—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	8.39e-05	0.000236	CcSEcCtD
Pramipexole—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.000236	CcSEcCtD
Pramipexole—Rash—Nelfinavir—acquired immunodeficiency syndrome	8.36e-05	0.000235	CcSEcCtD
Pramipexole—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	8.35e-05	0.000235	CcSEcCtD
Pramipexole—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	8.35e-05	0.000235	CcSEcCtD
Pramipexole—Hypotension—Ritonavir—acquired immunodeficiency syndrome	8.34e-05	0.000235	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	8.33e-05	0.000235	CcSEcCtD
Pramipexole—Rash—Stavudine—acquired immunodeficiency syndrome	8.33e-05	0.000235	CcSEcCtD
Pramipexole—Fatigue—Delavirdine—acquired immunodeficiency syndrome	8.32e-05	0.000234	CcSEcCtD
Pramipexole—Dermatitis—Stavudine—acquired immunodeficiency syndrome	8.32e-05	0.000234	CcSEcCtD
Pramipexole—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	8.31e-05	0.000234	CcSEcCtD
Pramipexole—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	8.31e-05	0.000234	CcSEcCtD
Pramipexole—Headache—Nelfinavir—acquired immunodeficiency syndrome	8.3e-05	0.000234	CcSEcCtD
Pramipexole—Headache—Stavudine—acquired immunodeficiency syndrome	8.28e-05	0.000233	CcSEcCtD
Pramipexole—Vomiting—Abacavir—acquired immunodeficiency syndrome	8.28e-05	0.000233	CcSEcCtD
Pramipexole—Confusional state—Lamivudine—acquired immunodeficiency syndrome	8.27e-05	0.000233	CcSEcCtD
Pramipexole—Pain—Delavirdine—acquired immunodeficiency syndrome	8.26e-05	0.000233	CcSEcCtD
Pramipexole—Constipation—Delavirdine—acquired immunodeficiency syndrome	8.26e-05	0.000233	CcSEcCtD
Pramipexole—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	8.25e-05	0.000232	CcSEcCtD
Pramipexole—Asthenia—Zidovudine—acquired immunodeficiency syndrome	8.24e-05	0.000232	CcSEcCtD
Pramipexole—Rash—Abacavir—acquired immunodeficiency syndrome	8.21e-05	0.000231	CcSEcCtD
Pramipexole—Dermatitis—Abacavir—acquired immunodeficiency syndrome	8.2e-05	0.000231	CcSEcCtD
Pramipexole—Oedema—Lamivudine—acquired immunodeficiency syndrome	8.2e-05	0.000231	CcSEcCtD
Pramipexole—Anorexia—Saquinavir—acquired immunodeficiency syndrome	8.19e-05	0.000231	CcSEcCtD
Pramipexole—Headache—Abacavir—acquired immunodeficiency syndrome	8.15e-05	0.00023	CcSEcCtD
Pramipexole—Infection—Lamivudine—acquired immunodeficiency syndrome	8.14e-05	0.000229	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	8.13e-05	0.000229	CcSEcCtD
Pramipexole—Nausea—Nevirapine—acquired immunodeficiency syndrome	8.13e-05	0.000229	CcSEcCtD
Pramipexole—Pruritus—Zidovudine—acquired immunodeficiency syndrome	8.12e-05	0.000229	CcSEcCtD
Pramipexole—Insomnia—Ritonavir—acquired immunodeficiency syndrome	8.07e-05	0.000227	CcSEcCtD
Pramipexole—Shock—Lamivudine—acquired immunodeficiency syndrome	8.06e-05	0.000227	CcSEcCtD
Pramipexole—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	8.04e-05	0.000226	CcSEcCtD
Pramipexole—Hypotension—Saquinavir—acquired immunodeficiency syndrome	8.03e-05	0.000226	CcSEcCtD
Pramipexole—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	8.03e-05	0.000226	CcSEcCtD
Pramipexole—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	8.02e-05	0.000226	CcSEcCtD
Pramipexole—Urticaria—Efavirenz—acquired immunodeficiency syndrome	8.02e-05	0.000226	CcSEcCtD
Pramipexole—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	7.98e-05	0.000225	CcSEcCtD
Pramipexole—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.98e-05	0.000225	CcSEcCtD
Pramipexole—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.96e-05	0.000224	CcSEcCtD
Pramipexole—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.96e-05	0.000224	CcSEcCtD
Pramipexole—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	7.96e-05	0.000224	CcSEcCtD
Pramipexole—Somnolence—Ritonavir—acquired immunodeficiency syndrome	7.94e-05	0.000224	CcSEcCtD
Pramipexole—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	7.92e-05	0.000223	CcSEcCtD
Pramipexole—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	7.89e-05	0.000222	CcSEcCtD
Pramipexole—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.87e-05	0.000222	CcSEcCtD
Pramipexole—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	7.87e-05	0.000222	CcSEcCtD
Pramipexole—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	7.86e-05	0.000221	CcSEcCtD
Pramipexole—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.86e-05	0.000221	CcSEcCtD
Pramipexole—Nausea—Stavudine—acquired immunodeficiency syndrome	7.85e-05	0.000221	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	7.83e-05	0.000221	CcSEcCtD
Pramipexole—Anorexia—Lamivudine—acquired immunodeficiency syndrome	7.81e-05	0.00022	CcSEcCtD
Pramipexole—Insomnia—Saquinavir—acquired immunodeficiency syndrome	7.77e-05	0.000219	CcSEcCtD
Pramipexole—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.76e-05	0.000219	CcSEcCtD
Pramipexole—Nausea—Abacavir—acquired immunodeficiency syndrome	7.73e-05	0.000218	CcSEcCtD
Pramipexole—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	7.72e-05	0.000217	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.71e-05	0.000217	CcSEcCtD
Pramipexole—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.7e-05	0.000217	CcSEcCtD
Pramipexole—Urticaria—Delavirdine—acquired immunodeficiency syndrome	7.67e-05	0.000216	CcSEcCtD
Pramipexole—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.66e-05	0.000216	CcSEcCtD
Pramipexole—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	7.66e-05	0.000216	CcSEcCtD
Pramipexole—Hypotension—Lamivudine—acquired immunodeficiency syndrome	7.66e-05	0.000216	CcSEcCtD
Pramipexole—Somnolence—Saquinavir—acquired immunodeficiency syndrome	7.64e-05	0.000215	CcSEcCtD
Pramipexole—Pain—Ritonavir—acquired immunodeficiency syndrome	7.63e-05	0.000215	CcSEcCtD
Pramipexole—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.63e-05	0.000215	CcSEcCtD
Pramipexole—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	7.63e-05	0.000215	CcSEcCtD
Pramipexole—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.63e-05	0.000215	CcSEcCtD
Pramipexole—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.59e-05	0.000214	CcSEcCtD
Pramipexole—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	7.56e-05	0.000213	CcSEcCtD
Pramipexole—Pruritus—Indinavir—acquired immunodeficiency syndrome	7.56e-05	0.000213	CcSEcCtD
Pramipexole—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	7.47e-05	0.00021	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	7.47e-05	0.00021	CcSEcCtD
Pramipexole—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	7.43e-05	0.000209	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	7.42e-05	0.000209	CcSEcCtD
Pramipexole—Insomnia—Lamivudine—acquired immunodeficiency syndrome	7.41e-05	0.000209	CcSEcCtD
Pramipexole—Fatigue—Saquinavir—acquired immunodeficiency syndrome	7.41e-05	0.000209	CcSEcCtD
Pramipexole—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	7.36e-05	0.000207	CcSEcCtD
Pramipexole—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	7.36e-05	0.000207	CcSEcCtD
Pramipexole—Pain—Saquinavir—acquired immunodeficiency syndrome	7.35e-05	0.000207	CcSEcCtD
Pramipexole—Constipation—Saquinavir—acquired immunodeficiency syndrome	7.35e-05	0.000207	CcSEcCtD
Pramipexole—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	7.31e-05	0.000206	CcSEcCtD
Pramipexole—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	7.31e-05	0.000206	CcSEcCtD
Pramipexole—Vomiting—Zidovudine—acquired immunodeficiency syndrome	7.3e-05	0.000206	CcSEcCtD
Pramipexole—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	7.3e-05	0.000206	CcSEcCtD
Pramipexole—Somnolence—Lamivudine—acquired immunodeficiency syndrome	7.29e-05	0.000205	CcSEcCtD
Pramipexole—Rash—Zidovudine—acquired immunodeficiency syndrome	7.24e-05	0.000204	CcSEcCtD
Pramipexole—Asthenia—Efavirenz—acquired immunodeficiency syndrome	7.24e-05	0.000204	CcSEcCtD
Pramipexole—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	7.23e-05	0.000204	CcSEcCtD
Pramipexole—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	7.22e-05	0.000203	CcSEcCtD
Pramipexole—Headache—Zidovudine—acquired immunodeficiency syndrome	7.19e-05	0.000203	CcSEcCtD
Pramipexole—Pruritus—Efavirenz—acquired immunodeficiency syndrome	7.14e-05	0.000201	CcSEcCtD
Pramipexole—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	7.13e-05	0.000201	CcSEcCtD
Pramipexole—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	7.11e-05	0.0002	CcSEcCtD
Pramipexole—Urticaria—Ritonavir—acquired immunodeficiency syndrome	7.09e-05	0.0002	CcSEcCtD
Pramipexole—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	7.08e-05	0.000199	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	7.08e-05	0.000199	CcSEcCtD
Pramipexole—Fatigue—Lamivudine—acquired immunodeficiency syndrome	7.07e-05	0.000199	CcSEcCtD
Pramipexole—Dizziness—Indinavir—acquired immunodeficiency syndrome	7.06e-05	0.000199	CcSEcCtD
Pramipexole—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	7.06e-05	0.000199	CcSEcCtD
Pramipexole—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	7.06e-05	0.000199	CcSEcCtD
Pramipexole—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	7.03e-05	0.000198	CcSEcCtD
Pramipexole—Pain—Lamivudine—acquired immunodeficiency syndrome	7.01e-05	0.000197	CcSEcCtD
Pramipexole—Constipation—Lamivudine—acquired immunodeficiency syndrome	7.01e-05	0.000197	CcSEcCtD
Pramipexole—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.93e-05	0.000195	CcSEcCtD
Pramipexole—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.9e-05	0.000194	CcSEcCtD
Pramipexole—Pruritus—Delavirdine—acquired immunodeficiency syndrome	6.83e-05	0.000192	CcSEcCtD
Pramipexole—Urticaria—Saquinavir—acquired immunodeficiency syndrome	6.83e-05	0.000192	CcSEcCtD
Pramipexole—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.82e-05	0.000192	CcSEcCtD
Pramipexole—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	6.79e-05	0.000191	CcSEcCtD
Pramipexole—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.79e-05	0.000191	CcSEcCtD
Pramipexole—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.79e-05	0.000191	CcSEcCtD
Pramipexole—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	6.75e-05	0.00019	CcSEcCtD
Pramipexole—Rash—Indinavir—acquired immunodeficiency syndrome	6.73e-05	0.00019	CcSEcCtD
Pramipexole—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.73e-05	0.00019	CcSEcCtD
Pramipexole—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	6.7e-05	0.000189	CcSEcCtD
Pramipexole—Headache—Indinavir—acquired immunodeficiency syndrome	6.69e-05	0.000188	CcSEcCtD
Pramipexole—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.67e-05	0.000188	CcSEcCtD
Pramipexole—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.61e-05	0.000186	CcSEcCtD
Pramipexole—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	6.58e-05	0.000185	CcSEcCtD
Pramipexole—Urticaria—Lamivudine—acquired immunodeficiency syndrome	6.51e-05	0.000183	CcSEcCtD
Pramipexole—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.48e-05	0.000183	CcSEcCtD
Pramipexole—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	6.48e-05	0.000183	CcSEcCtD
Pramipexole—Vomiting—Efavirenz—acquired immunodeficiency syndrome	6.42e-05	0.000181	CcSEcCtD
Pramipexole—Asthenia—Ritonavir—acquired immunodeficiency syndrome	6.41e-05	0.00018	CcSEcCtD
Pramipexole—Dizziness—Delavirdine—acquired immunodeficiency syndrome	6.38e-05	0.00018	CcSEcCtD
Pramipexole—Rash—Efavirenz—acquired immunodeficiency syndrome	6.36e-05	0.000179	CcSEcCtD
Pramipexole—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	6.36e-05	0.000179	CcSEcCtD
Pramipexole—Nausea—Indinavir—acquired immunodeficiency syndrome	6.34e-05	0.000179	CcSEcCtD
Pramipexole—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	6.33e-05	0.000178	CcSEcCtD
Pramipexole—Headache—Efavirenz—acquired immunodeficiency syndrome	6.32e-05	0.000178	CcSEcCtD
Pramipexole—Pruritus—Ritonavir—acquired immunodeficiency syndrome	6.32e-05	0.000178	CcSEcCtD
Pramipexole—Asthenia—Saquinavir—acquired immunodeficiency syndrome	6.16e-05	0.000174	CcSEcCtD
Pramipexole—Vomiting—Delavirdine—acquired immunodeficiency syndrome	6.14e-05	0.000173	CcSEcCtD
Pramipexole—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	6.11e-05	0.000172	CcSEcCtD
Pramipexole—Rash—Delavirdine—acquired immunodeficiency syndrome	6.09e-05	0.000171	CcSEcCtD
Pramipexole—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	6.08e-05	0.000171	CcSEcCtD
Pramipexole—Pruritus—Saquinavir—acquired immunodeficiency syndrome	6.08e-05	0.000171	CcSEcCtD
Pramipexole—Headache—Delavirdine—acquired immunodeficiency syndrome	6.05e-05	0.00017	CcSEcCtD
Pramipexole—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	6.04e-05	0.00017	CcSEcCtD
Pramipexole—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.99e-05	0.000169	CcSEcCtD
Pramipexole—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.9e-05	0.000166	CcSEcCtD
Pramipexole—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.88e-05	0.000166	CcSEcCtD
Pramipexole—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.88e-05	0.000166	CcSEcCtD
Pramipexole—Pruritus—Lamivudine—acquired immunodeficiency syndrome	5.8e-05	0.000163	CcSEcCtD
Pramipexole—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.73e-05	0.000162	CcSEcCtD
Pramipexole—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.68e-05	0.00016	CcSEcCtD
Pramipexole—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.68e-05	0.00016	CcSEcCtD
Pramipexole—Rash—Ritonavir—acquired immunodeficiency syndrome	5.63e-05	0.000159	CcSEcCtD
Pramipexole—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.62e-05	0.000158	CcSEcCtD
Pramipexole—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.61e-05	0.000158	CcSEcCtD
Pramipexole—Headache—Ritonavir—acquired immunodeficiency syndrome	5.59e-05	0.000158	CcSEcCtD
Pramipexole—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.46e-05	0.000154	CcSEcCtD
Pramipexole—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.42e-05	0.000153	CcSEcCtD
Pramipexole—Rash—Saquinavir—acquired immunodeficiency syndrome	5.42e-05	0.000153	CcSEcCtD
Pramipexole—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.41e-05	0.000152	CcSEcCtD
Pramipexole—Headache—Saquinavir—acquired immunodeficiency syndrome	5.38e-05	0.000152	CcSEcCtD
Pramipexole—Nausea—Ritonavir—acquired immunodeficiency syndrome	5.3e-05	0.000149	CcSEcCtD
Pramipexole—Vomiting—Lamivudine—acquired immunodeficiency syndrome	5.21e-05	0.000147	CcSEcCtD
Pramipexole—Rash—Lamivudine—acquired immunodeficiency syndrome	5.17e-05	0.000146	CcSEcCtD
Pramipexole—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	5.16e-05	0.000145	CcSEcCtD
Pramipexole—Headache—Lamivudine—acquired immunodeficiency syndrome	5.14e-05	0.000145	CcSEcCtD
Pramipexole—Nausea—Saquinavir—acquired immunodeficiency syndrome	5.1e-05	0.000144	CcSEcCtD
Pramipexole—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.87e-05	0.000137	CcSEcCtD
Pramipexole—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.59e-05	0.000511	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.57e-05	0.000509	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.56e-05	0.000508	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.56e-05	0.000508	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.54e-05	0.000504	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.49e-05	0.000497	CbGpPWpGaD
Pramipexole—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.48e-05	0.000496	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.48e-05	0.000496	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.46e-05	0.000494	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.43e-05	0.000489	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.43e-05	0.000489	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.43e-05	0.000489	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.43e-05	0.000489	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—ALB—acquired immunodeficiency syndrome	3.42e-05	0.000487	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.41e-05	0.000486	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.41e-05	0.000485	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.41e-05	0.000485	CbGpPWpGaD
Pramipexole—DRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.41e-05	0.000485	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.39e-05	0.000482	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.38e-05	0.000482	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.37e-05	0.00048	CbGpPWpGaD
Pramipexole—DRD3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.36e-05	0.000479	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.36e-05	0.000478	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.36e-05	0.000478	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.35e-05	0.000478	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.35e-05	0.000478	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.34e-05	0.000475	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.32e-05	0.000474	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.32e-05	0.000472	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.28e-05	0.000467	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.27e-05	0.000466	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.25e-05	0.000463	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.24e-05	0.000462	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.23e-05	0.000461	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.2e-05	0.000456	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.2e-05	0.000456	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—ALB—acquired immunodeficiency syndrome	3.19e-05	0.000455	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.19e-05	0.000454	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.15e-05	0.000449	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.15e-05	0.000448	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.13e-05	0.000447	CbGpPWpGaD
Pramipexole—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.1e-05	0.000442	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.1e-05	0.000442	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.1e-05	0.000441	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.09e-05	0.000441	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.09e-05	0.000441	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.07e-05	0.000438	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.07e-05	0.000438	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.06e-05	0.000436	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.05e-05	0.000435	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.05e-05	0.000435	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.05e-05	0.000434	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.05e-05	0.000434	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.03e-05	0.000432	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.01e-05	0.000429	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.01e-05	0.000429	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.01e-05	0.000429	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.01e-05	0.000428	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.01e-05	0.000428	CbGpPWpGaD
Pramipexole—DRD5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.96e-05	0.000422	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.96e-05	0.000422	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.96e-05	0.000422	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.95e-05	0.000421	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.94e-05	0.000418	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.93e-05	0.000417	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.91e-05	0.000415	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.91e-05	0.000414	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.89e-05	0.000412	CbGpPWpGaD
Pramipexole—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	2.89e-05	0.000412	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.86e-05	0.000407	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.85e-05	0.000407	CbGpPWpGaD
Pramipexole—SLC22A2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.84e-05	0.000405	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.83e-05	0.000404	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.83e-05	0.000404	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.83e-05	0.000403	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.83e-05	0.000403	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.81e-05	0.000401	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.81e-05	0.0004	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.81e-05	0.0004	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.8e-05	0.000398	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.79e-05	0.000398	CbGpPWpGaD
Pramipexole—ADRA2B—Hemostasis—IL2—acquired immunodeficiency syndrome	2.77e-05	0.000395	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.77e-05	0.000394	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.75e-05	0.000392	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.75e-05	0.000392	CbGpPWpGaD
Pramipexole—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	2.7e-05	0.000384	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.7e-05	0.000384	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.69e-05	0.000383	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.68e-05	0.000382	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.67e-05	0.00038	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.67e-05	0.00038	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.66e-05	0.000379	CbGpPWpGaD
Pramipexole—SLC22A1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.65e-05	0.000378	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.65e-05	0.000377	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.63e-05	0.000375	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.63e-05	0.000375	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.61e-05	0.000372	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—ALB—acquired immunodeficiency syndrome	2.59e-05	0.00037	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.59e-05	0.000369	CbGpPWpGaD
Pramipexole—ADRA2C—Hemostasis—IL2—acquired immunodeficiency syndrome	2.59e-05	0.000369	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.57e-05	0.000367	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.57e-05	0.000366	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.55e-05	0.000364	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.55e-05	0.000364	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.55e-05	0.000363	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.53e-05	0.00036	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.53e-05	0.00036	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.52e-05	0.000358	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.51e-05	0.000358	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.44e-05	0.000347	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.43e-05	0.000345	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.37e-05	0.000338	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.37e-05	0.000338	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.37e-05	0.000337	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.36e-05	0.000336	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.34e-05	0.000333	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.33e-05	0.000333	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.33e-05	0.000332	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.32e-05	0.00033	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.3e-05	0.000328	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.3e-05	0.000328	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.3e-05	0.000327	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.29e-05	0.000327	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.29e-05	0.000327	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.29e-05	0.000326	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.29e-05	0.000326	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.28e-05	0.000325	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.28e-05	0.000325	CbGpPWpGaD
Pramipexole—HTR1D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.27e-05	0.000323	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.25e-05	0.000321	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.25e-05	0.000321	CbGpPWpGaD
Pramipexole—HTR1B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.22e-05	0.000316	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.22e-05	0.000316	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.22e-05	0.000316	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.22e-05	0.000316	CbGpPWpGaD
Pramipexole—DRD4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.19e-05	0.000311	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.15e-05	0.000306	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.14e-05	0.000305	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.12e-05	0.000302	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.12e-05	0.000302	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.11e-05	0.0003	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.11e-05	0.0003	CbGpPWpGaD
Pramipexole—ADRA2A—Hemostasis—IL2—acquired immunodeficiency syndrome	2.1e-05	0.0003	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.09e-05	0.000298	CbGpPWpGaD
Pramipexole—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.09e-05	0.000297	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.06e-05	0.000294	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.06e-05	0.000293	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.03e-05	0.000289	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.03e-05	0.000289	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.02e-05	0.000287	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.01e-05	0.000287	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.01e-05	0.000287	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2e-05	0.000285	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2e-05	0.000285	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.98e-05	0.000283	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.98e-05	0.000282	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.98e-05	0.000282	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.000281	CbGpPWpGaD
Pramipexole—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.97e-05	0.00028	CbGpPWpGaD
Pramipexole—DRD3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.94e-05	0.000277	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.94e-05	0.000276	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.92e-05	0.000273	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.89e-05	0.00027	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.83e-05	0.00026	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.81e-05	0.000257	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.000257	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.8e-05	0.000257	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.8e-05	0.000257	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.79e-05	0.000255	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.78e-05	0.000253	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.76e-05	0.000251	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.75e-05	0.00025	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.74e-05	0.000248	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.73e-05	0.000247	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.72e-05	0.000245	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.71e-05	0.000243	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.69e-05	0.000241	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.69e-05	0.00024	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.68e-05	0.00024	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.66e-05	0.000237	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.64e-05	0.000233	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.63e-05	0.000232	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.59e-05	0.000227	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.59e-05	0.000226	CbGpPWpGaD
Pramipexole—DRD5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.58e-05	0.000225	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.57e-05	0.000224	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.56e-05	0.000223	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.54e-05	0.000219	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.53e-05	0.000218	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.53e-05	0.000218	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.52e-05	0.000217	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.51e-05	0.000215	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.51e-05	0.000215	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.49e-05	0.000212	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.49e-05	0.000212	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.48e-05	0.000211	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.46e-05	0.000208	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.38e-05	0.000196	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.37e-05	0.000195	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.000193	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.35e-05	0.000192	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.35e-05	0.000192	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—ALB—acquired immunodeficiency syndrome	1.33e-05	0.00019	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000189	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.33e-05	0.000189	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—ALB—acquired immunodeficiency syndrome	1.3e-05	0.000185	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—ALB—acquired immunodeficiency syndrome	1.24e-05	0.000177	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.23e-05	0.000176	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.22e-05	0.000173	CbGpPWpGaD
Pramipexole—HTR1D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.21e-05	0.000172	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000172	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.19e-05	0.00017	CbGpPWpGaD
Pramipexole—HTR1B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000169	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000167	CbGpPWpGaD
Pramipexole—DRD4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.17e-05	0.000166	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.12e-05	0.000159	CbGpPWpGaD
Pramipexole—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.11e-05	0.000159	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.06e-05	0.00015	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—ALB—acquired immunodeficiency syndrome	1.05e-05	0.00015	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.05e-05	0.00015	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000148	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000148	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.4e-06	0.000134	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.35e-06	0.000133	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.34e-06	0.000133	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.08e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.03e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.03e-06	0.000129	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.98e-06	0.000128	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.78e-06	0.000125	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.74e-06	0.000124	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.97e-06	0.000114	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.93e-06	0.000113	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.84e-06	0.000112	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.8e-06	0.000111	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.15e-06	0.000102	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.13e-06	0.000102	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.1e-06	0.000101	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7e-06	9.98e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.89e-06	9.82e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.58e-06	9.37e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.2e-06	8.84e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.12e-06	8.72e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.53e-06	7.87e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.33e-06	7.6e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.31e-06	7.56e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.16e-06	7.35e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.68e-06	6.67e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.61e-06	6.57e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.19e-06	5.97e-05	CbGpPWpGaD
